Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press115110.17650/1726-9776-2006-2-4-40-44DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак предстательной железыAndrocur in therapy of patients with prostate cancerАндрокур в терапии больных раком предстательной железыRusakovI. G.РусаковИ. Г.
Russian Federation
P.A. Herzen Moscow Research Oncological InstituteМНИОИ им. П. А. Герцена301220062440441702202017022020https://oncourology.abvpress.ru/oncur/article/view/1151

Androcur is one of basic drugs for the hormonal treatment of patients with prostate cancer. A great number of randomized studies showing the efficacy of androcur alone and in combination with other hormonal treatments have been completed. When orally or intramuscularly administered, the drug is well tolerated, showing the equal efficacy. Androcur used before treatment with luteinizing hormone-realizing hormone agonists is effective in inhibiting the «flash» syndrome. A combination of the agent with surgical or medical castration enhances the efficiency of therapy and improves the quality of life, by reducing the incidence of adverse reactions, such as hot flashes and hyperhidrosis. Androcur therapy prior to radical prostatectomy decreases the frequency of positive surgical edge while neoadjuvant therapy used before radiotherapy enhances the efficiency of radiation and reduces the number of local recurrences.

.

1. Чиссов В. И., Старинский В. В. Заболеваемость злокачественными новообразованиями в России. М., 2006.Чиссов В. И., Старинский В. В. Заболеваемость злокачественными новообразованиями в России. М., 2006.2. Матвеев Б. П. Клиническая онкоурология. М., 2003. с. 435—553.Матвеев Б. П. Клиническая онкоурология. М., 2003. с. 435—553.3. Huggins C., Hoges C. V. Studies on prostate cancer. The effect of castration. Cancer Res 1941; 385—402.Huggins C., Hoges C. V. Studies on prostate cancer. The effect of castration. Cancer Res 1941; 385—402.4. Neumann F. Pharmacological basis for clinical use of antiandrogens. Steroid Biochem 1983; 19(1A): 391—402.Neumann F. Pharmacological basis for clinical use of antiandrogens. Steroid Biochem 1983; 19(1A): 391—402.5. Knuth U.A., Hano R., Nieschlag E. Effect of flutamide or cyproterone acetate on pituitary and testicular hormones in normal men. J Clin Endocrinol Metab 1994; 59 (5): 963—9.Knuth U.A., Hano R., Nieschlag E. Effect of flutamide or cyproterone acetate on pituitary and testicular hormones in normal men. J Clin Endocrinol Metab 1994; 59 (5): 963—9.6. Geller J., Vazka G., Fruchtman B. et al. The effect of cyproterone acetate on advanced carcinoma of the prostate. Surg Gynecol Obstet 1968; 127: 748—58.Geller J., Vazka G., Fruchtman B. et al. The effect of cyproterone acetate on advanced carcinoma of the prostate. Surg Gynecol Obstet 1968; 127: 748—58.7. Smith R.B., Walsh P.C., Goodwin W.E. Cyproterone acetate in the treatment of advanced carcinoma of the prostate. J Urol 1973; 110; 106—8.Smith R.B., Walsh P.C., Goodwin W.E. Cyproterone acetate in the treatment of advanced carcinoma of the prostate. J Urol 1973; 110; 106—8.8. Altwein J.E., Jacobi G.H., Hohenfellner R. Estrogen versus cyproterone acetate in untreated inoperable carcinoma of the prostate: first results of an open, prospective, randomized study. Abstracts 3rd Congress of the European Association of Urology, Monte Carlo, 1978.Altwein J.E., Jacobi G.H., Hohenfellner R. Estrogen versus cyproterone acetate in untreated inoperable carcinoma of the prostate: first results of an open, prospective, randomized study. Abstracts 3rd Congress of the European Association of Urology, Monte Carlo, 1978.9. Jacobi G.H., Altwein J.E., Kurth K.H. et al. Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomized trial. Br J Urol 1980; 52: 208—15.Jacobi G.H., Altwein J.E., Kurth K.H. et al. Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomized trial. Br J Urol 1980; 52: 208—15.10. Varenhorst E., Wallentin L., Risberg B. The effects of orchiectomy, estrogens and cyproterone acetate on the antithrombin III concentration in carcinoma of the prostate. Urol Res 1981; 9: 25—8.Varenhorst E., Wallentin L., Risberg B. The effects of orchiectomy, estrogens and cyproterone acetate on the antithrombin III concentration in carcinoma of the prostate. Urol Res 1981; 9: 25—8.11. Tunn U.W., Senge Th., Jacobi G.H. Clinical experience with cyproterone acetate as monotherapy in inoperable carcinoma of the prostate. The therapy of advanced carcinoma of the prostate. Schering AG, Germany; 1984. p. 67—75.Tunn U.W., Senge Th., Jacobi G.H. Clinical experience with cyproterone acetate as monotherapy in inoperable carcinoma of the prostate. The therapy of advanced carcinoma of the prostate. Schering AG, Germany; 1984. p. 67—75.12. Pavone-Macaluso M., de Voogt H.J., Viggiano G. et al. Comparison of diethyl-stilbestrol, CPA and medroxy-progesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organisation for Research and Treatment of Cancer. J Urol 1986; 136: 624—31.Pavone-Macaluso M., de Voogt H.J., Viggiano G. et al. Comparison of diethyl-stilbestrol, CPA and medroxy-progesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organisation for Research and Treatment of Cancer. J Urol 1986; 136: 624—31.13. Schroder E.H., Whelan P., Kurth KH et al. A Preliminary Report on EORTC Protocol 30892. Schroder E.H. (ed): Recent Advances in Prostate Cancer and BPH. Proceedings of the PACIOU IV-Congress, 1996. Parthenon, N.Y., London; 1996. p. 141—6.Schroder E.H., Whelan P., Kurth KH et al. A Preliminary Report on EORTC Protocol 30892. Schroder E.H. (ed): Recent Advances in Prostate Cancer and BPH. Proceedings of the PACIOU IV-Congress, 1996. Parthenon, N.Y., London; 1996. p. 141—6.14. Schulze R., Senge Th. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate. J Urol 1990; 144: 934—41.Schulze R., Senge Th. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate. J Urol 1990; 144: 934—41.15. Waxman J., Williams G., Sandow J. et al. The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue. Am J Clin Oncol 1988; 11 (Suppl 2): 152—5.Waxman J., Williams G., Sandow J. et al. The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue. Am J Clin Oncol 1988; 11 (Suppl 2): 152—5.16. Theib M., Wirth M., Tunn U. et al. Cyproterone acetate + triptorelin versus placebo and triptorelin: multicenter phase III study in 222 patients with advanced prostatic carcinoma. XLVIII Congress of the German Urological Society, Dusseldorf; 1996.Theib M., Wirth M., Tunn U. et al. Cyproterone acetate + triptorelin versus placebo and triptorelin: multicenter phase III study in 222 patients with advanced prostatic carcinoma. XLVIII Congress of the German Urological Society, Dusseldorf; 1996.17. Thorpe S.C., Azmatullah S., Fellows G.J. et al. A prospective, randomized study to compare goserelin acetate (Zoladex®) versus cyproterone acetate (Cyprostat®) versus a combination of the two in the treatment of metastatic prostatic carcinoma. Eur Urol 1996; 29: 47—54.Thorpe S.C., Azmatullah S., Fellows G.J. et al. A prospective, randomized study to compare goserelin acetate (Zoladex®) versus cyproterone acetate (Cyprostat®) versus a combination of the two in the treatment of metastatic prostatic carcinoma. Eur Urol 1996; 29: 47—54.18. Eaton A.C., McGuire N. Cyproterone acetate in the treatment of post-orchiectomy hot flushes. Double-blind cross-over trial. Lancet 1983; 2 (8363): 1336—7.Eaton A.C., McGuire N. Cyproterone acetate in the treatment of post-orchiectomy hot flushes. Double-blind cross-over trial. Lancet 1983; 2 (8363): 1336—7.19. Kramer E., Andrzejak-Nolten N., Kallischnigg G., Neumann E. Prevention of hot flushes with CPA in the hormonal treatment of prostatic cancer — results of a placebo-controlled double-blind trial. Proceedings 3rd International Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment Paris (1992); p. 3—7.Kramer E., Andrzejak-Nolten N., Kallischnigg G., Neumann E. Prevention of hot flushes with CPA in the hormonal treatment of prostatic cancer — results of a placebo-controlled double-blind trial. Proceedings 3rd International Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment Paris (1992); p. 3—7.20. Tunn U.W., Goldschmidt A.J.W. Effects of temporary antiandrogenic treatment prior to radical prostatectomy. Murphy G., Khoury S., Chatelain C., Denis L (eds.): Recent Advances in Urological Cancers — Diagnosis and Treatment. Paris, 1990. p. 102—7.Tunn U.W., Goldschmidt A.J.W. Effects of temporary antiandrogenic treatment prior to radical prostatectomy. Murphy G., Khoury S., Chatelain C., Denis L (eds.): Recent Advances in Urological Cancers — Diagnosis and Treatment. Paris, 1990. p. 102—7.21. Goldenberg S.L., Klotz L.H., Srigley J. et al. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. J Urol 1996; 156: 873—7.Goldenberg S.L., Klotz L.H., Srigley J. et al. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. J Urol 1996; 156: 873—7.22. Porter A.T., Elhilali M., Manji M. et al. A phase III randomized trial to evaluate the efficacy of neoadjuvant therapy prior to curative radio-therapy in locally advanced prostate cancer patients — a Canadian Urologic Oncology Group Study. J Clin Oncol 1997; 16: 315a, abstr. 1123.Porter A.T., Elhilali M., Manji M. et al. A phase III randomized trial to evaluate the efficacy of neoadjuvant therapy prior to curative radio-therapy in locally advanced prostate cancer patients — a Canadian Urologic Oncology Group Study. J Clin Oncol 1997; 16: 315a, abstr. 1123.